Switch theme
Sign up to access all valuation multiples
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company’s core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.
1999
260
LTM Revenue $95.1M
LTM EBITDA $23.6M
$550M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surgical Science has a last 12-month revenue of $95.1M and a last 12-month EBITDA of $23.6M.
In the most recent fiscal year, Surgical Science achieved revenue of $87.8M and an EBITDA of $22.3M.
Surgical Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surgical Science valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $87.7M | $87.8M | XXX | XXX | XXX |
| Gross Profit | $52.8M | $60.9M | XXX | XXX | XXX |
| Gross Margin | 60% | 69% | XXX | XXX | XXX |
| EBITDA | $32.2M | $22.3M | XXX | XXX | XXX |
| EBITDA Margin | 37% | 25% | XXX | XXX | XXX |
| Net Profit | $18.7M | $23.2M | XXX | XXX | XXX |
| Net Margin | 21% | 26% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Surgical Science's stock price is SEK 126 (or $13).
Surgical Science has current market cap of SEK 6.4B (or $640M), and EV of SEK 5.5B (or $550M).
See Surgical Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $550M | $640M | XXX | XXX | XXX | XXX | $0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Surgical Science has market cap of $640M and EV of $550M.
Surgical Science's trades at 5.8x LTM EV/Revenue multiple, and 23.3x LTM EBITDA.
Analysts estimate Surgical Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Surgical Science and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $550M | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 24.7x | XXX | XXX | XXX |
| P/E | 49.0x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | 61.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSurgical Science's NTM/LTM revenue growth is 26%
Surgical Science's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Surgical Science's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Surgical Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Surgical Science and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 51% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 51% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surgical Science acquired XXX companies to date.
Last acquisition by Surgical Science was XXXXXXXX, XXXXX XXXXX XXXXXX . Surgical Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Surgical Science founded? | Surgical Science was founded in 1999. |
| Where is Surgical Science headquartered? | Surgical Science is headquartered in Sweden. |
| How many employees does Surgical Science have? | As of today, Surgical Science has 260 employees. |
| Who is the CEO of Surgical Science? | Surgical Science's CEO is Mr. Gisli Hennermark. |
| Is Surgical Science publicy listed? | Yes, Surgical Science is a public company listed on STO. |
| What is the stock symbol of Surgical Science? | Surgical Science trades under SUS ticker. |
| When did Surgical Science go public? | Surgical Science went public in 2017. |
| Who are competitors of Surgical Science? | Similar companies to Surgical Science include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Surgical Science? | Surgical Science's current market cap is $640M |
| What is the current revenue of Surgical Science? | Surgical Science's last 12-month revenue is $95.1M. |
| What is the current EBITDA of Surgical Science? | Surgical Science's last 12-month EBITDA is $23.6M. |
| What is the current EV/Revenue multiple of Surgical Science? | Current revenue multiple of Surgical Science is 5.8x. |
| What is the current EV/EBITDA multiple of Surgical Science? | Current EBITDA multiple of Surgical Science is 23.3x. |
| What is the current revenue growth of Surgical Science? | Surgical Science revenue growth between 2023 and 2024 was 0%. |
| Is Surgical Science profitable? | Yes, Surgical Science is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
